Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“Risk-Based vs Annual Breast Cancer Screening – What Did the WISDOM Trial Show?
The WISDOM Trial, published in JAMA, randomized over 28,000 women (age 40–74) to either annual mammography or a personalized, risk-based screening strategy.
The risk-based group underwent:
- Genetic testing (9 susceptibility genes)
- Polygenic risk scoring
- Clinical risk modeling
Based on risk level, women received:
- 6-monthly alternating MRI/mammography (highest risk)
- Annual mammography (elevated risk)
- Biennial mammography (average risk)
- Delayed screening (low risk, age 40–49)
Main Results (median follow-up 5.1 years)
- Risk-based screening was noninferior to annual screening for stage ≥IIB cancers.
- In the highest-risk group, no stage ≥IIB cancers were observed.
- Despite fewer mammograms overall, biopsy rates were not reduced.
- Cancer detection and imaging intensity appropriately increased with rising risk.
- 89% of women in the observational cohort preferred the risk-based approach.”
Other articles featuring Elvina Almuradova on OncoDaily.